Scientists have discovered a compound in python blood that reduces appetite and could lead to safer, more effective weight-loss drugs.

In a move clearly designed to strengthen its position among developers, OpenAI has acquired Python tool maker Astral. The house of Altman expects the deal to strengthen the ecosystem for its Codex ...

OpenAI Group PBC today announced plans to acquire Astral Software Inc., a startup with a set of widely used Python development tools.  The terms of the deal were not disclosed. Astral’s development ...

OpenAI announced Thursday that it has entered into an agreement to acquire Astral, the company behind popular open source Python development tools such as uv, Ruff, and ty, and integrate the company ...

Python is now one of the fastest-growing programming languages being used globally and supports machine-learning-based ...

Metabolites from python blood have the potential to lead to the creation of weight-loss medications similar to Ozempic, according to new research. At first, scientists at Stanford University, Baylor ...

A reticulated python has already completed its hunt of this small deer and is in the process of constricting its prey.

OpenAI on Thursday announced the acquisition of Astral, the developer of open source Python tools that include uv, Ruff and ty. It says that it plans to integrate them with Codex, its AI coding agent ...

OpenAI acquires Astral, the Python toolmaker, to enhance Codex AI coding assistant as it competes with Anthropic's Claude Code and Cursor.

OpenAI to acquire Astral, bringing Python tools like uv, Ruff, and ty into Codex as it moves from code generation to executing full developer workflows.